Psychomotor depressive symptoms may differentially respond to venlafaxine Predicting differential antidepressant efficacy remains an elusive goal in major depressive disorder (MDD). The aims of this study were three-fold. Firstly, to examine if psychomotor retardation symptoms (item 8 on the 17-item Hamilton Depression Rating Scale) improve preferentially to venlafaxine (VEN) over escitalopram (ESC) treatment. Secondly, whether the 18 item CORE psychomotor signs scale predicted antidepressant remission. Finally, to investigate the role of two norepinephrine transporter gene (NET) polymorphisms (rs2242446 and rs5569) on antidepressant efficacy. Adults with Diagnostic and Statistical Manual of Mental Disorders, 4th ed. MDD (n = 113) were treated with ESC or VEN prospectively for 8 weeks and rated serially with the Hamilton Depression Rating Scale. In a subsample (n = 51) of patients from one of the three recruitment sites, the CORE psychomotor signs scale was also administered at baseline. Participants treated with VEN had significantly greater reduction in psychomotor retardation symptoms than those treated with ESC. The CORE scale did not predict antidepressant response or remission. Neither NET polymorphism moderated antidepressant efficacy. Findings suggest possible preferential utility of a selective serotonin and noradrenaline reuptake inhibitor in cases of MDD presenting with greater psychomotor retardation. The moderate to small sample size makes a type II error risk possible, and the negative findings need to be interpreted with caution. The positive finding of preferential efficacy of VEN for psychomotor retardation symptoms has potential translational utility. Int Clin Psychopharmacol 00:000-000 c 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Noradrenaline appears to have various important roles in the central nervous system, particularly in mediating arousal states (Ressler and Nemeroff, 1999) . Multiple lines of evidence suggested that the noradrenergic system is disordered in major depressive disorder (MDD) (Potter et al., 1993; Schatzberg and Schildkraut, 1995; Heninger et al., 1996; Leonard, 1997; Owens et al., 1997; Owens, 1997; Charney, 1998) . Noradrenergic dysfunction in MDD may produce a subset of depressive symptoms. Reduced noradrenergic activity may contribute to decreased concentration, mental and physical slowing, poor energy, tiredness, and reduced self-care (Nutt, 2008) . These symptoms may be particularly impairing in work and social settings (Tse and Bond, 2002) . Other studies have suggested that noradrenaline reuptake inhibitors preferentially treat social drive and functioning better than selective serotonin reuptake inhibitors (SSRIs) (Dubini et al., 1997; Massana et al., 1999) .
Item 8 of the Hamilton Depression Rating Scale (HDRS) examines slowness of thought and speech, impaired ability to concentrate, and decreased motor activity, and rates it on a 0-4 scale. A subanalysis of data from a study comparing the selective serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran with the SSRI paroxetine (Kasper, 1997) found item 8 of the HDRS preferentially improved with milnacipran. In a study of 182 patients with Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)-defined MDD, participants were assessed at baseline and 12 months after naturalistic clinical care (Parker et al., 2001) . The CORE scale measures 18 psychomotor signs (noninteractiveness, retardation, and agitation subscales), which are rated (score 0-3) at the end of a clinical interview (Parker and Hadzi-Pavlovic, 1996; Joyce et al., 2002) . Higher CORE scale scores were associated with better response to electroconvulsive therapy, tricyclic antidepressants, and the irreversible monoamine oxidase inhibitors compared to other treatments such as SSRIs and psychotherapy (Parker and Hadzi-Pavlovic, 1996; Parker et al., 1999; Parker et al., 2001) . But it is unclear whether the wider psychomotor signs captured in the CORE scale has greater antidepressant response predictive utility than baseline HDRS severity alone (Fournier et al., 2009; Fournier et al., 2010) .
The norepinephrine transporter (NET) is a sodiumdependent transporter, which reuptakes norepinephrine into the neuron for both cyclic use and termination of the action of norepinephrine at the synapse (Amara and Kuhar, 1993; Uhl and Johnson, 1994; Béïque et al., 1998) . Several studies have examined the role of NET polymorphisms in mood and related disorders with no statistically significant associations found (Owen et al., 1999; Leszczynska-Rodziewicz et al., 2002; Samochowiec et al., 2002; Zill et al., 2002; Chang et al., 2007; Dong et al., 2009; Min et al., 2009; Uher et al., 2009; Baffa et al., 2010) . This is counter balanced by positive associations in other studies suggesting NET rs2242446 and NET rs5569 single nucleotide polymorphisms (SNPs) may predict preferential response to noradrenergic over serotonergic antidepressants in MDD (Higuchi et al., 2003; Ryu et al., 2004; Yoshida et al., 2004; Kim et al., 2006; Baffa et al., 2010) . These associations are mechanistically plausible given the rs2242446 polymorphism is located in the NET promoter region and appears to alter transcription (Zill et al., 2002) . In addition, the synonymous rs5569 polymorphism in exon 6 has been linked to alternative mRNA splicing and reduced NET functioning (Sogawa et al., 2010) , and has been associated with preferential response to noradrenergic antidepressants (Kim et al., 2006) .
The aims of this study were to explore both clinical and genetic moderating factors of antidepressant efficacy. The primary aim was to examine whether psychomotor retardation symptoms (item 8 on HDRS) improve preferentially to the SNRI venlafaxine (VEN) over the SSRI escitalopram (ESC). The secondary aim was to examine whether the CORE scale at baseline predicted antidepressant remission controlled for baseline HDRS score severity. The tertiary aim was to examine whether two NET polymorphisms (rs2242446 and rs5569) predict differential antidepressant efficacy between VEN and ESC.
Materials and methods
There were three recruitment sites -two in Australia (Melbourne and Geelong) and one in Singapore. Participants were either of Caucasian (European Australian) or Asian (Han Chinese, Singaporean) backgrounds. Patients 18 years and over with a principal diagnosis of MDD (DSM-IV criteria, assessed by semistructured clinical interview) were studied. A body of evidence suggests that more severe episodes of MDD have better response rates to antidepressants than milder cases (Sotsky et al., 1991; Paykel et al., 1988; Khan et al., 2005; Fournier et al., 2010) , thus a HDRS score of at least 18 was required to exclude milder cases of MDD, which may be less medication responsive. Patients who had treatment refractory depression (Z 3 failed medication trials) were excluded. Patients were studied prospectively for 8 weeks with HDRS ratings as the primary outcome measure. Antidepressant response was defined as at least 50% reduction in HDRS from baseline (Zajecka, 2003; Moncrieff and Kirsch, 2005) . Clinical Global Impression scales for improvement and severity were used to guide clinical dose adjustment (Berk et al., 2008) . A subgroup of participants from one of the recruitment sites (Geelong) had baseline CORE scale data collected (Parker and Hadzi-Pavlovic, 1996) . Ratings were blinded to genotype. Before commencement there was a drug washout period (five half-lives of the previous agent) for participants already receiving an antidepressant. During the first week all patients received a standard dose of either ESC 10 mg/ day or VEN 75 mg/day. Drug selection was based on patient's preference of side-effect profile. At weeks 1, 4, and 8 of treatment doses were adjusted on a clinical basis, with the dose escalated if there was no improvement on the Clinical Global Impression Scale, or the dose reduced if problematic side effects emerged [elevation of the UKU side effects scale (Lingjaerde et al., 1987) with patient intolerance reported]. No other psychotropic medications were given and psychotherapy was not commenced during the study period. Two candidate NET SNPs (rs2242446 and rs5569) were genotyped. In addition, genotyping of CYP2D6 and CYP2C19 polymorphisms was conducted to control for metabolized status, and 5HTTLPR genotype was also assayed as potential antidepressant efficacy confounders (Porcelli et al., 2011; Singh et al., 2012) . The study was approved by the relevant research ethics committees (Study 138, The Melbourne Clinic, Richmond, Australia; and Changi Hospital, Singapore).
Genotyping
DNA was extracted from each sample using QIAamp DNA Mini Kit (Qiagen Inc., Chadstone, Victoria, Australia) from venous blood or buccal brush samples. Genotypes of candidate (NET rs2242446 and rs5569) and potential confounding (CYP2D6 and CYP2C19 metabolizer status, and 5HTTLPPR s and l genotype) (Porcelli et al., 2011) were determined by the PCR followed by single primer extension and analysis on a Sequenom Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 384-well genetic analysis system.
Statistical analysis
Data were analyzed using SPSS (version 19; SPSS Inc., Chicago, Illinois, USA). Differences in categorical and continuous demographic data by treatment received (ESC or VEN) were examined using w 2 and t-tests, respectively. For the primary analysis, intention-to-treat analysis was applied. Repeated-measures analysis of variance was used to determine changes in HDRS item 8 by antidepressant type. Logistic regression was used to estimate the odds of responding to ESC or VEN based on HDRS item 8 and CORE baseline scores. To examine whether either of the two NET polymorphisms moderated treatment efficacy, interaction terms were created (e.g. HDRS Â NET and CORE Â NET) and included in the regression models. The CubeX program was applied to detect departures from Hardy-Weinberg Equilibrium (HWE) and estimate pairwise linkage disequilibrium (LD) measures r 2 and D 0 (Gaunt et al., 2007) . Polymorphisms with HWE greater than 0.01 were considered to be in equilibrium. LD was assumed if a pair of SNPs had r 2 and D 0 values greater than 0.80 with haplotype analysis performed if LD existed.
Results
Of 113 participants enrolled in the study, 98 had sufficient data to determine antidepressant efficacy. At baseline, six participants had a HDRS less than 18 so were excluded from the analysis, two participants withdrew consent before assessment, and seven participants withdrew before either week 4 or 8 HDRS ratingpreventing determination of medication efficacy. A subgroup of participants had baseline CORE scale administered (n = 51). Table 1 displays the baseline features of participants included in the analysis (n = 98) of differential antidepressant efficacy for psychomotor retardation (item 8 of the HDRS) stratified by medication. No confounders were noted among clinical, demographic, and genetic characteristics ( Table 1) . The rs2242226 and rs5569 NET polymorphisms did not differ by treatment group, were in HWE (P > 0.10), and were not in LD (D 0 = 0.13, r 2 = 0.02). Thus, haplotype analysis was not necessary.
Treatment effects on psychomotor symptom reduction
The response rate by antidepressant was not significantly different, with the VEN response rate 63.4% and the ESC response rate 73.7% (z = 1.07, P = 0.284). Participants receiving VEN had significantly greater reductions in psychomotor retardation (item 8 HDRS, n = 41) compared to those receiving ESC (n = 57) (Fig. 1) . Specifically, those receiving VEN had greater reductions in psychomotor retardation at weeks 4 (t = 6.53, d.f. = 96, P < 0.001) and 8 (t = 6.36, d.f. = 96, P < 0.001) compared to ESC-treated participants.
Effects of psychomotor symptoms on treatment response
Item 8 on the HDRS significantly predicted VEN but not ESC response (Table 2) . Specifically, for every one point increase on item 8 of the HDRS we observed a 6.98 (95% confidence interval = 1.28-37.8) increase odds of responding to 8 weeks of VEN treatment. This effect was not found to be moderated by either of the NET polymorphisms (P > 0.45). Neither baseline item 8 on the HDRS or baseline CORE scale score (total score or subscale scores) predicted antidepressant remission.
Discussion
These data indicate that psychomotor retardation symptoms may preferentially improve with VEN (SNRI) compared to ESC (SSRI). This suggests that participants No significant differences in demographic, clinical, or genetic features were noted for either the full sample of participants or the subgroup that had the CORE scale administered in addition to the HDRS. CYP2D6 metabolizer status genotyping failed for one of the ESC-treated participants. CGI, Clinical Global Impression Scale; CORE, the Core psychomotor signs scale; ESC, escitalopram; HDRS, 17-item Hamilton Depression Rating Scale; VEN, venlafaxine.
with greater psychomotor symptoms (such as poor drive and attention) could preferentially benefit from VEN and possibly other SNRIs (Kasper, 1997) . Psychomotor retardation may reflect noradrenergic dysfunction (Nutt, 2008) and this may be concordant with our finding. This psychomotor retardation symptom cluster has particular social and vocational consequences in MDD, thus is an important symptom subset of MDD to target (Dubini et al., 1997; Kasper, 1997; Massana et al., 1999; Tse and Bond, 2002) . Should the current findings be replicated this will add weight to the possible clinical utility of prescribers tailoring the type of antidepressant (noradrenergic activity) to the level of psychomotor retardation symptoms.
Response (Z 50% reduction in total HDRS score) was not predicted by either item 8 of the HDRS or the CORE scale at baseline, controlling for baseline severity. The overall remission rate from MDD was not significantly different by medication type nor predicted by baseline psychomotor signs. Our data, however, indicate that the psychomotor retardation symptom cluster may predict specific antidepressant efficacy. Different types of antidepressant medication may have differential subsyndrome efficacy patterns despite no discernible difference being present at the global syndrome level.
Several limitations of the current study must be considered before making firm interpretation of the data. Although 113 participants were recruited, only 98 participants completed the treatment phase of the study for analysis of the role of item 8 and NET polymorphisms to antidepressant response. This is a moderate sample size. Only 51 participants had a baseline CORE scale score recordeda small sample risking type II error. Thus, the negative findings in this study need to be interpreted with caution. The positive finding that VEN preferentially improves item 8 (psychomotor retardation symptoms) also needs to be interpreted with some caution due to further limitation of the study design and potential confounders.
Although various clinical, demographic, and genetic factors were controlled for in this study, multiple other genetic and environmental factors probably influence antidepressant response. An example of this is differential childhood trauma and recent stress levels influencing antidepressant response, possibly mediated by epigenetic mechanisms (Keers et al., 2011; Nanni et al., 2012) . Not controlling for this in the sample of 98 participants analyzed and other confounders leave the data vulnerable to type I error due to a mediating factor rather than VEN leading to the greater reduction in psychomotor retardation symptoms. Antidepressant dose is also a factor to consider.
In our study, VEN was not escalated beyond 300 mg during the 8-week treatment phase, but could be escalated further (at clinical discretion) after the study period. Some literature suggests patients may require up to 450 mg for efficacy (Thase et al., 2006 , Mbaya et al., 2002 . As VEN's Ki for serotonin is much lower than for noradrenaline (Béïque et al., 1998) , it is possible participants on lower doses of VEN had minimal noradrenergic reuptake inhibition even at doses as high as 300 mg/day (Debonnel et al., 2007) . Extending to treatment phase of the study to 10 or 12 weeks would have enabled higher doses of VEN be reached and included in the analysis.
Inclusion of participants with baseline HDRS under 25 raise issues of poorer antidepressant response rates for antidepressants versus placebo, as participants with baseline HDRS greater than 25 separate more robustly from placebo on meta-analysis (Fournier et al., 2010) . However, other studies have indicated that even a HDRS in the range 13-25 can separate from placebo with amitriptyline (Paykel et al., 1988) but only HDRS greater than 28 did in another study (Khan et al., 2005) . We adopted HDRS greater than 18 as a compromise between these various findings. A more severe depressed cohort of patients with more melancholic symptoms may have assisted the robustness of our findings and relevance to more severe cases of MDD. Strengths of our study include the prospective naturalistic blinded design, control for potential pharmacokinetic (P450) and pharmacodynamic (5HTTLPR) potential genetic confounders, and control for baseline HDRS and differential antidepressant overall response rates by medication.
Other noradrenergic agents such as reboxetine may have beneficial effects on motor function (Zittel et al., 2007) and could also be studied for differential antidepressant efficacy on psychomotor features of MDD to help guide prescribers. Future studies may help shed more light on whether VEN and other noradrenergic antidepressants have specific efficacy for psychomotor symptoms. This is clinically relevant given the possibility that disabling psychomotor symptoms may preferentially respond to noradrenergic antidepressant.
